The enantioselective disposition kinetics of the benzimidazole anthelmintic, ricobendazole (RBZ), have been characterized after its intravenous (iv) and subcutaneous (sc) administration as a racemic formulation to cattle. The (+) and (-) RBZ enantiomeric forms were recovered in plasma after iv and sc administration of the racemic RBZ formulation, using a chiral phase based HPLC method. A biexponential plasma concentration versus time curve was observed for both RBZ enantiomers following the iv treatment. Total body clearance was higher for (-) RBZ (150.4 mL/h. kg) compared with that obtained for the (+) RBZ antipode (78.1 mL/h. kg). The elimination half-life of the (-) RBZ enantiomer was shorter (T1/2beta: 2.67 h) compared with the (+) enantiomer (T1/2beta: 5.41 h). The plasma availability (expressed as AUC) was significantly higher for (+) RBZ compared with that obtained for the (-) antipode following both treatments. The enantiomeric ratio in plasma at T(0) was close to unity (50% of each enantiomer); the analysis of the concentration ratios (+) RBZ/(-) RBZ, demonstrated an increase in the proportion of (+) RBZ during the time course of the kinetics after both iv and sc treatments. The results presented herein show the enantioselective disposition kinetics of RBZ in cattle and are a further contribution to the understanding of the kinetic behaviour of these sulphoxide-containing benzimidazole anthelmintics in ruminants.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/bdd.246 | DOI Listing |
J Chromatogr A
January 2025
School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, PR China. Electronic address:
Evodiamine, a chiral quinazoline alkaloid in the traditional Chinese medicine Evodiae fructus, exhibited efficacy for CNS diseases. In this study, the pure enantiomers of evodiamine were prepared in large quantities via chemical resolution. Their structures were elucidated by MS, NMR and ECD.
View Article and Find Full Text PDFBMC Psychiatry
January 2025
Department of Psychiatry, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
Background: Ketamine is a promising therapy for treatment-resistant depression due to its rapid onset, although benefits are often transitory, with patients needing maintenance therapy to prevent relapse. Most data supporting ketamine for treatment-resistant depression refers to the intravenous route of administration, leaving alternative routes lacking in data, especially as maintenance regimens. Moreover, the safety of ketamine maintenance therapy is poorly defined.
View Article and Find Full Text PDFBrain Sci
December 2024
Department of Biophysics and Pharmacology, Federal University of Rio Grande do Norte, Natal 59078-900, Brazil.
Background/objectives: Recent studies have investigated the effects of ketamine on fear memory in animals. However, it is unclear if ketamine might affect avoidance memory and emotional behaviors concomitantly. In this study, we compared the effects of (,)- and ()-ketamine in modulating avoidance responses, depression- and anxiety-related behaviors in stressed mice.
View Article and Find Full Text PDFJ Agric Food Chem
January 2025
School of Pharmaceutical Sciences, Liaoning University, 66 Chongshan Road, Shenyang 110036, Liaoning Province, P. R. China.
Clethodim is a chiral herbicide with two enantiomers. The herbicidal activity of (-)-clethodim is 1.3-2.
View Article and Find Full Text PDFJ Psychopharmacol
January 2025
Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Background: Ketamine has demonstrated both rapid and sustained efficacy in treating depression, especially in treatment-resistant cases. However, concerns regarding the addictive potential of ketamine during long-term depression treatment persist among clinicians.
Aim: This review aimed to summarise the evidence on addiction phenomena associated with ketamine treatment of depression.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!